Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117740 | 0.82 | STS (0.64) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL3249170 | 0.82 | KDM4E (0.61) | STSGPR119KDM4EPKM | |
| SCHEMBL931999 | 0.82 | MEN1 (0.72) | KDM4EMEN1KMT2A | |
| SCHEMBL2158159 | 0.81 | GPR119 (0.65) | STSGPR119KDM4EPKM | |
| SCHEMBL28398406 | 0.81 | STS (0.48) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL1653114 | 0.80 | KDM4E (0.62) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL19022363 | 0.78 | HPGD (0.57) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL5449587 | 0.78 | STS (0.62) | STSGPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL18338006 | 0.78 | KLK7 (0.52) | KDM4EMEN1KMT2A | |
| SCHEMBL18338005 | 0.78 | KLK7 (0.52) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324251-B2 | Cyclic modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2008042926-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093798-A1 | CYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CXCR1, CCR3 | STS 2708/4885GPR119 240/4885PTPN2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.